Abeona Therapeutics vs Stoke Therapeutics
ABEO and STOK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABEO and STOK compare
Stoke Therapeutics is the larger company, worth 12 times as much as Abeona Therapeutics ($1.7B against $138M).
Abeona Therapeutics keeps more of each dollar of sales as profit, with a net margin of −160% compared with −754% at Stoke Therapeutics.
Abeona Therapeutics scores higher on the StockData Score (8 against 6 for Stoke Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABEO | STOK |
|---|---|---|
| Size and price | ||
| Market cap | $138M | $1.7B |
| Share price | $2.42 | $26.68 |
| Change, 1 year | −51.0% | 6.2% |
| Change, 5 years | −86.9% | −4.0% |
| Beta (5Y) | 1.30 | 1.62 |
| Employees | 226 | 170 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.5× (better) | 62.4× |
| P/B | 1.1× (better) | 5.0× |
| FCF yield | −47.9% | −10.5% (better) |
| Fair value | $3.99 | $9.57 |
| Margin of safety | 39.4% (better) | −179% |
| Growth | ||
| Revenue growth (TTM) | – | −86.2% |
| Revenue growth, 5Y average | −10.3% | – |
| Net income growth (TTM) | −176% (better) | −496% |
| EPS growth (TTM) | – | −501% |
| Profitability | ||
| Gross margin | 65.1% | – |
| Operating margin | −186% (better) | −810% |
| Net margin | −160% (better) | −754% |
| FCF margin | −170% (better) | −655% |
| Return on equity | −42.1% (better) | −61.1% |
| Return on invested capital | – | −252% |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.00 |
| Interest coverage | −24.5× (better) | −4856.0× |
| Current ratio | 5.69 | 7.69 (better) |
| Altman Z-score | −4.84 | 18.22 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 77.9% | 120% |
| Held by insiders | 12.3% | 41.6% |
| Insider net buying, 12 months | −$3.5M (better) | −$6.7M |
| Short interest, % of float | 33.6% | 28.5% |
Go deeper
- ABEO stock overview
- ABEO income statement
- ABEO valuation and score
- STOK stock overview
- STOK income statement
- STOK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.